Carl Shapiro is a panelist during the session titled “Some call it “newBrandeis” some call it hipster – either way, is there now such a thing as too big?”
For more information on this event, click here.
What’s 340B? An economist’s view of the recent wave of 340B litigation
But this change has led to complex relationships among pharmaceutical manufacturers, hospitals, pharmacies, and third-party administrators, increasing...
